X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (141) 141
glycopyrrolate (112) 112
index medicus (102) 102
male (91) 91
glycopyrrolate - administration & dosage (80) 80
female (78) 78
pharmacology & pharmacy (62) 62
pulmonary disease, chronic obstructive - drug therapy (57) 57
administration, inhalation (54) 54
adult (53) 53
pharmacokinetics (53) 53
glycopyrrolate - pharmacokinetics (51) 51
muscarinic antagonists - administration & dosage (50) 50
middle aged (48) 48
copd (46) 46
glycopyrrolate - adverse effects (42) 42
animals (41) 41
glycopyrrolate - therapeutic use (41) 41
obstructive pulmonary-disease (41) 41
double-blind method (39) 39
lung diseases, obstructive (39) 39
tiotropium (39) 39
bronchodilator agents - administration & dosage (38) 38
respiratory system (38) 38
aged (36) 36
efficacy (36) 36
safety (35) 35
glycopyrrolate - pharmacology (34) 34
treatment outcome (34) 34
chronic obstructive pulmonary disease (33) 33
muscarinic antagonists - adverse effects (32) 32
atropine (31) 31
heart rate - drug effects (29) 29
muscarinic antagonists - therapeutic use (29) 29
drug combinations (28) 28
glycopyrronium (28) 28
muscarinic antagonists - pharmacokinetics (27) 27
anesthesiology (26) 26
bronchodilator agents - adverse effects (26) 26
cross-over studies (26) 26
pulmonary disease, chronic obstructive - physiopathology (26) 26
bronchodilator agents - pharmacokinetics (23) 23
double-blind (23) 23
formoterol (22) 22
anesthesia (21) 21
drug therapy (21) 21
drug therapy, combination (21) 21
muscarinic antagonists - pharmacology (20) 20
severity of illness index (20) 20
dosage and administration (19) 19
dose-response relationship, drug (19) 19
time factors (19) 19
blood pressure - drug effects (18) 18
indacaterol (18) 18
metered dose inhalers (18) 18
bronchodilator agents - therapeutic use (17) 17
glycopyrrolate - blood (17) 17
adrenergic beta-2 receptor agonists - administration & dosage (16) 16
care and treatment (16) 16
diseases of the respiratory system (16) 16
formoterol fumarate - administration & dosage (16) 16
international journal of chronic obstructive pulmonary disease (16) 16
research (16) 16
glycopyrronium bromide (15) 15
injections, intravenous (15) 15
veterinary sciences (15) 15
drug administration schedule (14) 14
drug dosages (14) 14
pharmacology (14) 14
pulmonary disease, chronic obstructive - diagnosis (14) 14
analysis (13) 13
area under curve (13) 13
co-suspension delivery technology (13) 13
forced expiratory volume (13) 13
heart rate (13) 13
indans - administration & dosage (13) 13
quinolones - administration & dosage (13) 13
tiotropium bromide (13) 13
young adult (13) 13
drugs (12) 12
half-life (12) 12
lama (12) 12
lung - physiopathology (12) 12
neostigmine (12) 12
nva237 (12) 12
placebo (12) 12
atropine - administration & dosage (11) 11
clinical trials (11) 11
medicine & public health (11) 11
pharmacology/toxicology (11) 11
review (11) 11
toxicology (11) 11
administration, oral (10) 10
adolescent (10) 10
aged, 80 and over (10) 10
asthma (10) 10
complications and side effects (10) 10
drug interactions (10) 10
health aspects (10) 10
lung - drug effects (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Respiratory Medicine, ISSN 0954-6111, 05/2018, Volume 138, pp. 74 - 80
This study compared the efficacy, pharmacokinetics (PK), and safety of GFF MDI (Bevespi Aerosphere®), a fixed-dose combination of glycopyrronium and formoterol fumarate dihydrate... 
Co-suspension delivery technology | Metered dose inhaler | Formoterol fumarate dihydrate | Spacer | Valved holding chamber | Glycopyrronium | LUNG | CARDIAC & CARDIOVASCULAR SYSTEMS | CO-SUSPENSION(TM) DELIVERY TECHNOLOGY | DEPOSITION | COMBINATION | CHILDREN | RESPIRATORY SYSTEM | SPACER DEVICES | ASTHMA | COPD | Bronchodilator Agents - blood | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Pulmonary Disease, Chronic Obstructive - blood | Metered Dose Inhalers | Female | Bronchodilator Agents - adverse effects | Muscarinic Antagonists - blood | Formoterol Fumarate - blood | Glycopyrrolate - adverse effects | Severity of Illness Index | Inhalation Spacers | Formoterol Fumarate - adverse effects | Glycopyrrolate - blood | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Aged | Drug Combinations | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Chlorofluorocarbons | Parameters | Lung diseases | Pharmacology | Glycopyrrolate | Patients | Evidence-based medicine | Confidence intervals | Randomization | Concentration time | Obstructive lung disease | Formoterol | Chronic obstructive pulmonary disease | Safety | Pharmacokinetics | Drug dosages
Journal Article
International Journal of COPD, ISSN 1176-9106, 03/2018, Volume 13, pp. 945 - 953
... (NCT01854645, NCT01854658, NCT01970878) in patients with COPD. Here, we present findings from a pharmacokinetic (PK... 
Co-suspension delivery technology | Metered dose inhaler | Pharmacokinetics | Formoterol fumarate dihydrate | Glycopyrronium | COPD | DRUG | PLACEBO | EFFICACY | SAFETY | co-suspension delivery technology | MULTIPLE | OBSTRUCTIVE PULMONARY-DISEASE | COMBINATIONS | ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE | metered dose inhaler | RESPIRATORY SYSTEM | pharmacokinetics | glycopyrronium | formoterol fumarate dihydrate | Adrenergic beta-2 Receptor Agonists - pharmacokinetics | Bronchodilator Agents - blood | Bronchodilator Agents - administration & dosage | United States | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Biological Availability | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Adrenergic beta-2 Receptor Agonists - blood | Adrenergic beta-2 Receptor Agonists - adverse effects | Pulmonary Disease, Chronic Obstructive - blood | Aged, 80 and over | Metered Dose Inhalers | Adult | Female | Muscarinic Antagonists - pharmacokinetics | Bronchodilator Agents - adverse effects | Muscarinic Antagonists - blood | Formoterol Fumarate - blood | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - blood | Glycopyrrolate - pharmacokinetics | New Zealand | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Bronchodilator Agents - pharmacokinetics | Lung - drug effects | Formoterol Fumarate - pharmacokinetics | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Australia | Drug Combinations | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium | Medical research | Lung diseases, Obstructive | Care and treatment | Analysis | Medicine, Experimental | Formoterol | Drug therapy, Combination
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 2014, Volume 28, Issue 2, pp. 114 - 121
Journal Article
Journal of Veterinary Pharmacology and Therapeutics, ISSN 0140-7783, 06/2014, Volume 37, Issue 3, pp. 260 - 268
The disposition of plasma glycopyrrolate (GLY) is characterized by a three‐compartment pharmacokinetic model after a 1... 
HUMAN-PLASMA-CHOLINESTERASE | CLEARANCE | DONKEYS | PHARMACOLOGY | PHARMACOLOGY & PHARMACY | VETERINARY SCIENCES | METABOLITE | PROCAINE | ESTERASE | Animals | Area Under Curve | Half-Life | Female | Horses - metabolism | Male | Horses - blood | Glycopyrrolate - pharmacokinetics | Glycopyrrolate
Journal Article
Journal Article
Journal Article
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 02/2020, Volume 60, pp. 101873 - 101873
... combination in late-stage clinical development for chronic obstructive pulmonary disease (COPD). We conducted two studies to characterize the pharmacokinetic... 
Formoterol fumarate | Budesonide | Co-suspension delivery technology | Chronic obstructive pulmonary disease | Glycopyrrolate | Pharmacokinetics | DRUG | EFFICACY | SAFETY | DEPOSITION | OPEN-LABEL | RESPIRATORY SYSTEM | PHARMACOLOGY & PHARMACY | CROSSOVER | Index Medicus
Journal Article
Journal Article
Journal Article
AAPS PharmSciTech, ISSN 1530-9932, 2/2018, Volume 19, Issue 2, pp. 837 - 844
Journal Article
Spinal Cord, ISSN 1362-4393, 02/2015, Volume 53, Issue 2, pp. 103 - 108
Study design: Single centre, single ascending dose study. Objectives: To compare the pharmacokinetics and assess the safety of capromorelin, a compound that has potential to treat constipation following spinal cord injury (SCI... 
BOWEL EVACUATION |